Guggenheim Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective raised by analysts at Guggenheim from $148.00 to $150.00 in a research note issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price target would indicate a potential upside of 26.89% from the company’s current price. […]
More Stories
M&G Plc Grows Stock Position in Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM)
M&G Plc boosted its position in Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM – Free Report) by 27.1% in the third...
Crane NXT, Co. (NYSE:CXT) to Issue Quarterly Dividend of $0.16
Crane NXT, Co. (NYSE:CXT – Get Free Report) declared a quarterly dividend on Thursday, November 7th,Wall Street Journal reports. Shareholders...
uniQure (NASDAQ:QURE) Issues Earnings Results, Beats Expectations By $0.21 EPS
uniQure (NASDAQ:QURE – Get Free Report) issued its earnings results on Tuesday. The biotechnology company reported ($0.91) earnings per share...
Forrest Eugene Norrod Sells 40,540 Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD) Stock
Advanced Micro Devices, Inc. (NASDAQ:AMD – Get Free Report) EVP Forrest Eugene Norrod sold 40,540 shares of the firm’s stock...
JFrog (NASDAQ:FROG) Issues Q4 Earnings Guidance
JFrog (NASDAQ:FROG – Get Free Report) updated its fourth quarter earnings guidance on Thursday. The company provided earnings per share...
Insider Selling: BOK Financial Co. (NASDAQ:BOKF) Director Sells 2,000 Shares of Stock
BOK Financial Co. (NASDAQ:BOKF – Get Free Report) Director Steven Bangert sold 2,000 shares of the stock in a transaction...